MBX Biosciences
45 hedge funds and large institutions have $784M invested in MBX Biosciences in 2024 Q3 according to their latest regulatory filings, with 45 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
95.24% more ownership
Funds ownership: 0% → 95.24% (+95%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$137M |
| 2 |
O
OrbiMed
New York
|
+$87.2M |
| 3 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$82.7M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$69M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$67.2M |
Top Sellers
MBX Hedge Fund Activity: Q3 2024 in Review
45 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in MBX Biosciences (MBX) for Q3 2024, worth a combined $784M.
Buyers outnumbered sellers: 45 funds opened new MBX positions and 0 closed out — a net gain of 45 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Frazier Life Sciences Management, opening a new position worth an estimated $137M.
- 45 institutional investors held MBX Biosciences (MBX) as of Q3 2024, up from 0 in Q2 2024.
- Funds reported $784M of MBX Biosciences stock for Q3 2024.
- 45 funds opened new MBX Biosciences positions in Q3 2024 and 0 closed out, a net change of +45 holders.
- The largest MBX Biosciences buyer in Q3 2024 was Frazier Life Sciences Management, an estimated $137M added.
Based on aggregated 13F filings for Q3 2024.